Drug intelligence / Profile preview

NUC-3030

Development stage: Preclinical
Lead developer: Nucorion Pharmaceuticals
Modality: Small Molecules

Overview

NUC-3030 is an early-stage drug candidate being developed by Nucorion Pharmaceuticals for the treatment of solid tumors. The compound utilizes Nucorion's proprietary Liver Targeting Platform (LTP) technology, which is designed to selectively deliver therapeutic agents to the liver. This platform aims to increase the concentration of the active drug within liver tissues while reducing systemic exposure, thereby potentially improving efficacy and reducing off-target side effects. As of early 2024, NUC-3030 is in the lead identification phase of preclinical development.

Beyond the preview

Go deeper on NUC-3030.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUC-3030.

Explore the full profile